CENTRE LEON BERARD Patent applications |
Patent application number | Title | Published |
20150250770 | LKB1 AS PREDICTIVE MARKER OF EVEROLIMUS EFFICACY IN BREAST CANCER - Method for identifying a breast cancer likely to respond to treatment with everolimus comprising the following steps: Measuring the level of expression of the LKB 1 gene in a breast tumour sample previously taken from a breast cancer patient, Classifying the breast cancer as likely to respond to treatment with everolimus if the LKB1 gene is under-expressed in said breast tumour sample. | 09-10-2015 |
20140329261 | TREATMENT OF CANCER BY INHIBITION OF THE MYD88/ERK MAP KINASE INTERACTION - A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE. | 11-06-2014 |
20140186364 | INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA - The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells. | 07-03-2014 |
20140086923 | Antibodies Directed Against ICOS and Uses Thereof - The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg. | 03-27-2014 |
20130084564 | ASSESSMENT OF CANCER RISK BASED ON RNU2 CNV AND INTERPLAY BETWEEN RNU2 CNV AND BRCA1 - Polynucleotides useful for detecting copy number variation of RNU2 sequences and methods of assessing risk of developing breast or ovarian cancer using molecular combing and/or detection or quantification of BRCA1 expression. | 04-04-2013 |
20120220487 | Determination of 17q Gain in Neuroblastoma Patients by Analysis of Circulating DNA - Methods for diagnosis of neuroblastoma comprising determining whether there is a gain of genetic material from chromosome arm segment 17q21-qter in the circulating DNA of a human subject. | 08-30-2012 |
20120107826 | ZNF217 A New Prognostic And Predictive Biomarker Of Recurrent Invasive And Metastatic Phenotypes In Breast Cancer - The present invention relates to methods for determining the prognosis of a cancer. The methods involve determining the level of expression of the ZNF217 gene in a cancer cell sample or in a tumor sample wherein over-expression of ZNF217 is correlated with likelihood of metastasis and with likelihood of relapse/recurrence of the cancer. | 05-03-2012 |
20120076788 | C-CBL AND ANTAGONISTS THEREOF FOR THE TREATMENT AND DIAGNOSIS OF CANCER - The present invention relates to the treatment of cancer. More specifically, the present invention relates to the use of c-cbl as a marker for the diagnosis and/or prognosis of cancer, and to the use of a c-cbl antagonist for the treatment of a cancer associated with resistance to apoptosis. | 03-29-2012 |
20120015364 | METHOD FOR THE SELECTION OF ENDOTHELIAL CELLS DEATH INDUCERS VIA NETRIN-1 AND ITS APPLICATIONS - The present invention relates to an in vitro method for selecting a compound capable to induce the death of endothelial cells, preferably endothelial cells from vessels or neovessels. The invention further comprises the use of netrin-1 function inhibitors as compounds capable to induce the death of endothelial cells, preferably endothelial cells from vessels or neovessels of tumor expressing netrin-1. Finally, the invention relates to a kit for the selection of a compound capable to induce the death of endothelial cells. | 01-19-2012 |
20110229485 | INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA - The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain, or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells. | 09-22-2011 |